News

New CDC data shows nirsevimab, a long-acting monoclonal antibody, was highly effective in protecting infants from RSV-associated hospitalizations. RSV is the leading cause of hospitalization among infants in the U.S. For details, read the CDC news release.

The CDC recommends — which this study...

The CDC has issued a health advisory due to low vaccination rates against influenza, COVID-19, and RSV (respiratory syncytial virus), which could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Also, a recent increase in cases of multisystem inflammatory...

In response to a recent shortage of Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe RSV among infants and children — the CDC has announced the release of 77,000 additional doses for hospitals and providers.

Nirsevimab may be given in child's 1st year. Another...

Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe respiratory syncytial virus (RSV) among infants and children — is now available for providers to order. Nirsevimab may be given in child's 1st year and then their 2nd RSV season for some high-risk patients.  

RSV Vaccine for Babies, Toddlers: The FDA approved the 1st respiratory syncytial virus (RSV) vaccine for babies and toddlers. Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in children <24 months of age who remain vulnerable to severe RSV disease...